Nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are the
leading causes of chronic liver disease worldwide. NAFLD and ALD share …

NAFLD has become a major public health problem for more than 2 decades with a growing
prevalence in parallel with the epidemic of obesity and type 2 diabetes (T2D). The disease …

Non-alcoholic fatty liver disease (NAFLD) produces high morbidity and mortality rates. Its
worldwide prevalence is 25%, but evidence from Latin America (LA) is lacking. We aimed to …

Non-alcoholic fatty liver disease (NAFLD) affects 20–25% of the general population and is
associated with morbidity, increased mortality, and elevated health-care costs. Most NAFLD …

Purpose of review To assess the current challenges regarding liver diseases, including the
burden of disease, access to care, screening, and treatment needs in Latin America. Recent …

Background Non-alcoholic fatty liver disease (NAFLD) was previously a neglected disease
that is now becoming a worldwide pandemic. A better understanding of its incidence and …

In 2020, international consensus guidelines recommended the renaming of non-alcoholic
fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD), supported …

Background Non‐alcoholic fatty liver disease (NAFLD) is a major liver disease worldwide.
Bile acid dysregulation may be a key feature in its pathogenesis and progression. Aims To …

NAFLD and its inflammatory condition NASH, which is more likely to progress to fibrosis and
advanced liver disease, are the histologic manifestation of a heterogeneous disease closely …

Non-alcoholic fatty liver disease (NAFLD) is a common and prevalent disorder affecting 25
percent of the adults in the United States and 32 percent of adults globally. It is one of the …